- Home
- ALZN vs ATCH Comparison
ALZN vs ATCH Comparison
Compare ALZN & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- ATCH
- Stock Information
- Founded
- ALZN 2016
- ATCH 2022
- Country
- ALZN United States
- ATCH United States
- Employees
- ALZN N/A
- ATCH N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- ATCH
- Sector
- ALZN Health Care
- ATCH
- Exchange
- ALZN Nasdaq
- ATCH Nasdaq
- Market Cap
- ALZN 2.3M
- ATCH 2.5M
- IPO Year
- ALZN 2021
- ATCH N/A
- Fundamental
- Price
- ALZN $2.35
- ATCH $0.18
- Analyst Decision
- ALZN Strong Buy
- ATCH
- Analyst Count
- ALZN 1
- ATCH 0
- Target Price
- ALZN $180.00
- ATCH N/A
- AVG Volume (30 Days)
- ALZN 216.5K
- ATCH 30.2M
- Earning Date
- ALZN 09-10-2025
- ATCH 08-27-2025
- Dividend Yield
- ALZN N/A
- ATCH N/A
- EPS Growth
- ALZN N/A
- ATCH N/A
- EPS
- ALZN N/A
- ATCH N/A
- Revenue
- ALZN N/A
- ATCH $14,825,966.00
- Revenue This Year
- ALZN N/A
- ATCH N/A
- Revenue Next Year
- ALZN N/A
- ATCH N/A
- P/E Ratio
- ALZN N/A
- ATCH N/A
- Revenue Growth
- ALZN N/A
- ATCH 1066.77
- 52 Week Low
- ALZN $2.06
- ATCH $0.14
- 52 Week High
- ALZN $135.54
- ATCH $26.94
- Technical
- Relative Strength Index (RSI)
- ALZN 35.09
- ATCH 46.62
- Support Level
- ALZN $2.14
- ATCH $0.17
- Resistance Level
- ALZN $2.44
- ATCH $0.22
- Average True Range (ATR)
- ALZN 0.17
- ATCH 0.03
- MACD
- ALZN -0.03
- ATCH 0.00
- Stochastic Oscillator
- ALZN 23.97
- ATCH 22.77
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.